MedTrace Logo

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

NCT01801930 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-02-26

Study results available
· View outcomes & findings →

Summary

To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Conditions

Interventions

DRUG

OCV-103 and OCV-104

0.3 mg of each

DRUG

OCV-103 and OCV-104

1 mg of each

DRUG

OCV-103 and OCV-104

3 mg of each

DRUG

OCV-103 and OCV-104

6 mg of each

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Junichi Hashimoto, PhD · Otsuka Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801930 on ClinicalTrials.gov